- NervGen Pharma (NGEN) has completed its public offering for gross proceeds of $9,200,000
- The underwriters, led by iA Private Wealth Inc., purchased 3,680,000 units at a price of C$2.50 per unit, including the full exercise of the over-allotment option
- Net proceeds will be used for the continued development of their lead drug candidate, NVG-291, and general corporate purposes
- NervGen is restoring life’s potential by creating innovative treatments for nervous system injury
- NervGen Pharma Corp. (NGEN) opened trading at C$2.92 per share
NervGen Pharma (NGEN) has completed its public offering for gross proceeds of $9,200,000.
The underwriters, led by iA Private Wealth Inc., purchased 3,680,000 units at a price of C$2.50 per unit, including the full exercise of the over-allotment option. Each unit includes one common share and one-half of one common share purchase warrant. Each warrant can be exercised for one common share for a period of 24 months following the closing of the offering at an exercise price of C$3.20.
NervGen issued to the underwriters an aggregate of 257,600 broker warrants.
Net proceeds will be used for the continued development of their lead drug candidate, NVG-291, and general corporate purposes.
NervGen is restoring life’s potential by creating innovative treatments for nervous system injury due to trauma or disease of the nervous system.
NervGen Pharma Corp. (NGEN) opened trading at C$2.92 per share.
